Cyramza

Lilly gets fifth use for Cyramza with FDA liver cancer nod
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Pharmaforum
Eli Lilly
Cyramza
FDA
liver cancer
hepatocellular carcinoma
Flag link:
Lilly's combo treatment meets main goal in lung cancer late-stage study
Lilly's combo treatment meets main goal in lung cancer late-stage study
Yahoo/Reuters
Eli Lilly
Cyramza
clinical trials
metastatic non-small cell lung cancer
Roche
erlotinib
Flag link:
Lilly's Cyramza succeeds in late-stage liver cancer trial
Lilly's Cyramza succeeds in late-stage liver cancer trial
Yahoo/Reuters
Eli Lilly
Cyramza
liver cancer
clinical trials
Flag link:
Lilly Nixes Expansion of Stomach Cancer Drug After Mixed Study Results
Lilly Nixes Expansion of Stomach Cancer Drug After Mixed Study Results
Xconomy
Eli Lilly
stomach cancer
Cyramza
Flag link:
What Drove Eli Lilly’s Oncology Franchise in 1Q16?
What Drove Eli Lilly’s Oncology Franchise in 1Q16?
Yahoo/Market Realist
Eli Lilly
oncology
Alimta
Erbitux
Cyramza
Portrazza
Flag link:
Oncologists' pricing pushback mounts as docs snub costly me-too drugs
Oncologists' pricing pushback mounts as docs snub costly me-too drugs
Fierce Pharma
oncologists
drug pricing
me-too drugs
Cyramza
Eli Lilly
Flag link:
3 Top Big Pharmaceutical Stocks With Upcoming Catalysts
3 Top Big Pharmaceutical Stocks With Upcoming Catalysts
24/7 Wall St
AbbVie
Humira
Cyramza
Eli Lilly
generics
Evista
Cymbalta
Pfizer
Ibrance
Flag link:
AstraZeneca and Lilly to test new cancer drug combination
AstraZeneca and Lilly to test new cancer drug combination
Yahoo/Reuters
Eli Lilly
AstraZeneca
MEDI4736
Cyramza
anti-PD-L1
Flag link:
Good news for Lilly: Cyramza nabs yet another FDA approval
Good news for Lilly: Cyramza nabs yet another FDA approval
BioPharma Dive
Eli Lilly
Cyramza
FDA
colorectal cancer
Flag link:
Colorectal Cancer Treatment Market Value to Hit $9.4B by 2020
Colorectal Cancer Treatment Market Value to Hit $9.4B by 2020
Drug Discovery and Development
colorectal cancer
Avastin
Cyramza
nintedanib
Flag link:
Lilly leans on diabetes, Cyramza in predictions for 2015 growth
Lilly leans on diabetes, Cyramza in predictions for 2015 growth
Fierce Pharma
Eli Lilly
diabetes
Cyramza
Flag link:
FDA approves Eli Lilly’s Cyramza for lung cancer
FDA approves Eli Lilly’s Cyramza for lung cancer
Marketwatch
FDA
Eli Lilly
Cyramza
lung cancer
Flag link:
Lilly gains new stomach cancer approval for Cyramza
Lilly gains new stomach cancer approval for Cyramza
Pharmaphorum
Eli Lilly
stomach cancer
Cyramza
FDA
Flag link:
Lilly's Cyramza shows survival benefit in gastro cancers
Lilly's Cyramza shows survival benefit in gastro cancers
Pharma Times
Eli Lilly
Cyramza
gastric cancer
Flag link:
Lilly's Cyramza fails in liver cancer trial
Lilly's Cyramza fails in liver cancer trial
Yahoo/Reuters
Eli Lilly
Cyramza
liver cancer
Flag link:
ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy
ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy
Yahoo/Benzinga
ASCO
cancer
Imbruvica
JNJ
Eli Lilly
Cyramza
Flag link:
Eli Lilly reports CYRAMZA significantly improves survival in Phase 3 study
Eli Lilly reports CYRAMZA significantly improves survival in Phase 3 study
Yahoo/Fly on the Wall
Cyramza
Eli Lilly
ASCO
non-small cell lung cancer
Flag link:
Lilly Drug Extends Survival in Advanced Lung Cancer Patients
Lilly Drug Extends Survival in Advanced Lung Cancer Patients
The Street
Eli Lilly
lung cancer
Cyramza
Flag link:
6 Drugs That Could Move the Pharma Market
6 Drugs That Could Move the Pharma Market
Wall St Cheat Sheet
Gilead Sciences
Teva Pharmaceuticals
Copaxone
Idelalisib
Bristol-Myers Squibb
nivolumab
Cyramza
Eli Lilly
Pfizer
palbociclib
Sovaldi
Flag link: